Cargando…
Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study
Ultramicronized palmitoylethanolamide (um-PEA), a compound with antioxidant, anti-inflammatory and neuroprotective properties, appears to be a potential adjuvant treatment for early stages of Coronavirus disease 2019 (COVID-19). In our study, we enrolled 90 patients with confirmed diagnosis of COVID...
Autores principales: | Albanese, Maria, Marrone, Giulia, Paolino, Agostino, Di Lauro, Manuela, Di Daniele, Francesca, Chiaramonte, Carlo, D’Agostini, Cartesio, Romani, Annalisa, Cavaliere, Alessandro, Guerriero, Cristina, Magrini, Andrea, Mercuri, Nicola Biagio, Di Daniele, Nicola, Noce, Annalisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878249/ https://www.ncbi.nlm.nih.gov/pubmed/35215365 http://dx.doi.org/10.3390/ph15020253 |
Ejemplares similares
-
Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients
por: Noce, Annalisa, et al.
Publicado: (2021) -
Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation
por: Roncati, Luca, et al.
Publicado: (2021) -
Serological determinants of COVID-19
por: Noce, Annalisa, et al.
Publicado: (2020) -
Linking Migraine to Gut Dysbiosis and Chronic Non-Communicable Diseases
por: Di Lauro, Manuela, et al.
Publicado: (2023) -
Effects of Caloric Restriction Diet on Arterial Hypertension and Endothelial Dysfunction
por: Di Daniele, Nicola, et al.
Publicado: (2021)